ReviewJournal of clinical medicine2025
A Novel Protocol for Feasibility and Safety in Early Discharge with ACS.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute coronary syndrome is the primary reason for admission to cardiology services and involves significant resource consumption. Currently, low-risk patients are recommended for discharge within the first 48-72 h, enabling early initiation of cardiac rehabilitation with proper follow-up. This is crucial not only as an efficiency marker but also because current evidence has shown it to be a safe and feasible strategy. Thus, this work aims to provide a comprehensive review of the current evidence on early discharge in acute coronary syndrome and propose a new, intuitive, objective, and easy-to-use tool: the LATE2ACS protocol. This is a narrative, hypothesis-generating review; LATE2ACS is presented as a preliminary, exploratory checklist rather than a definitive or implementable score. Its added value lies in operationalizing post-PCI early discharge decision-making across ACS as a pragmatic bedside checklist that complements, rather than replaces, prognostic scores such as TIMI, GRACE, Zwolle, and CADILLAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.